|Bid||109.31 x 200|
|Ask||109.42 x 100|
|Day's range||105.13 - 109.81|
|52-week range||39.82 - 109.81|
|PE ratio (TTM)||-17.27|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
Last week an FDA advisory panel voted unanimously (10-0) to approve CTL019 (tisagenlecleucel-T), a novel CAR-T cell immunotherapy developed by Novartis (NVS), for the treatment of children and young adults (ages 3 - 25) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). B-cell ALL is a form of Leukemia (i.e.
It's time to look at these 5 CAR-T stocks given the interest generated by a positive FDA advisory panel vote for Novartis' (NVS) experimental CAR-T treatment.
CEOs don’t usually root for a competing company, but that’s precisely what Kite Pharma Inc.’s Arie Belldegrun did this week.